Show simple item record

dc.contributor.authorTellez Gabriel, Marta
dc.contributor.authorTekpli, Xavier
dc.contributor.authorReine, Trine M.
dc.contributor.authorHegge, Beate
dc.contributor.authorNielsen, Stephanie Rose
dc.contributor.authorChen, Meng
dc.contributor.authorMoi, Line
dc.contributor.authorNormann, Lisa Svartdal
dc.contributor.authorRasmussen Busund, Lill-Tove
dc.contributor.authorCalin, George A.
dc.contributor.authorMælandsmo, Gunhild Mari
dc.contributor.authorPerander, Maria
dc.contributor.authorTheocharis, Achilleas D.
dc.contributor.authorKolset, Svein Olav
dc.contributor.authorKnutsen, Erik
dc.date.accessioned2022-08-30T07:58:06Z
dc.date.available2022-08-30T07:58:06Z
dc.date.issued2022-04-14
dc.description.abstractSerglycin is a proteoglycan highly expressed by immune cells, in which its functions are linked to storage, secretion, transport, and protection of chemokines, proteases, histamine, growth factors, and other bioactive molecules. In recent years, it has been demonstrated that serglycin is also expressed by several other cell types, such as endothelial cells, muscle cells, and multiple types of cancer cells. Here, we show that serglycin expression is upregulated in transforming growth factor beta (TGF-b) induced epithelial-mesenchymal transition (EMT). Functional studies provide evidence that serglycin plays an important role in the regulation of the transition between the epithelial and mesenchymal phenotypes, and it is a significant EMT marker gene. We further find that serglycin is more expressed by breast cancer cell lines with a mesenchymal phenotype as well as the basal-like subtype of breast cancers. By examining immune staining and single cell sequencing data of breast cancer tissue, we show that serglycin is highly expressed by infiltrating immune cells in breast tumor tissue.en_US
dc.identifier.citationTellez Gabriel, Tekpli, Reine, Hegge, Nielsen, Chen, Moi, Normann, Rasmussen Busund, Calin, Mælandsmo, Perander, Theocharis, Kolset, Knutsen. Serglycin is Involved in TGF-β induced epithelial-mesenchymal transition and is highly expressed by immune cells in breast cancer tissue. Frontiers in Oncology. 2022;12:868868:1-13en_US
dc.identifier.cristinIDFRIDAID 2027948
dc.identifier.doi10.3389/fonc.2022.868868
dc.identifier.issn2234-943X
dc.identifier.urihttps://hdl.handle.net/10037/26465
dc.language.isoengen_US
dc.publisherFrontiers Mediaen_US
dc.relation.journalFrontiers in Oncology
dc.rights.accessRightsopenAccessen_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.titleSerglycin is Involved in TGF-β induced epithelial-mesenchymal transition and is highly expressed by immune cells in breast cancer tissueen_US
dc.type.versionpublishedVersionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record